Pulmonary endarterectomy vs balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension, BMC Pulmonary Medicine, August 6, 2025

A study recently published on BMC Pulmonary Medicine compared baseline characteristics and short-term efficacy of pulmonary endarterectomy (gold standard for operable chronic thromboembolic pulmonary hypertension, removing thickened intima and organized thrombus from pulmonary arteries) vs. balloon pulmonary angioplasty (an option for inoperable chronic thromboembolic pulmonary hypertension, improving blood flow by dilating stenosed/occluded vessels without removing lesions), particularly […]

Pulmonary endarterectomy vs balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension, BMC Pulmonary Medicine, August 6, 2025 Read Post »

Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Journal of the American College of Cardiologists, June 2025

While pulmonary endarterectomy (PEA) is the primary treatment in chronic thromboembolic pulmonary hypertension (CTEPH), it is not feasible for at least 40% of patients. Balloon pulmonary angioplasty (BPA) has emerged as an alternative for these patients.The International Balloon Pulmonary Angioplasty (BPA) Registry aimed to assess practices and outcomes across 18 centers in the U.S., Europe,

Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Journal of the American College of Cardiologists, June 2025 Read Post »

Balloon Pulmonary Angioplasty (BPA)’s development from its early applications to its current widespread adoption globally, Expert Review of Respiratory Medicine, April 14, 2025

Balloon Pulmonary Angioplasty (BPA) has revolutionized treatment for Chronic Thromboembolic Pulmonary Hypertension (CTEPH), as discussed in a comprehensive review published on April 14 2025 in the Expert Review of Respiratory Medicine. While Pulmonary Endarterectomy (PEA) continues to be the gold standard for patients with operable disease, many patients cannot undergo this surgical procedure due to

Balloon Pulmonary Angioplasty (BPA)’s development from its early applications to its current widespread adoption globally, Expert Review of Respiratory Medicine, April 14, 2025 Read Post »

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants!

The Alliance for Pulmonary Hypertension (AfPH) recently concluded its 14th webinar, marking the culmination of an educational initiative that began in June 2023. These virtual gatherings brought together internationally renowned experts in pulmonary hypertension, who shared their expertise on a comprehensive range of topics crucial to advancing patient care and quality of life. The diverse

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants! Read Post »

Virtual reality technology can improve patient well-being in intensive care settings, a promising solution for patients undergoing major surgery like lung transplant

According to Paul Wischmeyer, Professor of Anesthesiology and Surgery with Tenure and Director of Perioperative Research, at the Duke Clinical Research Institute, USA, virtual reality technology offers a promising solution to improve patient well-being in intensive care settings. Staying in intensive care can be an incredibly challenging and disorienting experience for patients. Many face severe

Virtual reality technology can improve patient well-being in intensive care settings, a promising solution for patients undergoing major surgery like lung transplant Read Post »

2025 International Society for Heart and Lung Transplant (ISHLT) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Conference, 26 April, 2025

The International CTEPH association (ICA) and International Society for Heart and Lung Transplant (ISHLT) are jointly organising the first CTEPH Conference, held on 26 April 2025 in Boston, USA alongside the ISHLT’s 45th Annual Meeting & Scientific Sessions. Read more at this link

2025 International Society for Heart and Lung Transplant (ISHLT) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Conference, 26 April, 2025 Read Post »

Recent report reveals wide regional variability in access to pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) for chronic thromboembolic pulmonary hypertension (CTEPH)

The CLARITY survey, the findings of which were published in the Pulmonary Circulation April 2024 issue (link), aimed to collect data on current chronic thromboembolic pulmonary hypertension (CTEPH) diagnosis, treatment, and management, and to identify unmet medical needs. Conducted from September 2021 to May 2022, the survey targeted hospital-based medical specialists via Scientific Societies and

Recent report reveals wide regional variability in access to pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) for chronic thromboembolic pulmonary hypertension (CTEPH) Read Post »

Sharing best practices in chronic thromboembolic pulmonary hypertension surgical and interventional treatments: insights from two world experts

The Alliance for Pulmonary Hypertension (AfPH) places a strong emphasis on the sharing of knowledge and best practices as a means to empower patients and family members and advance the understanding and treatment of pulmonary hypertension. This is the rationale behind the creation of the Pulmonary Hypertension Knowledge Sharing Platform, an open, inclusive, and dynamic

Sharing best practices in chronic thromboembolic pulmonary hypertension surgical and interventional treatments: insights from two world experts Read Post »

The lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages

Did you know that the lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages: English, French, German, Greek, Italian, Polish, Portuguese (Portugal), Russian, Spanish, Romanian, Ukrainian. The English version of the lay summary was developed with the active collaboration of the two

The lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages Read Post »

The fascinating story about how the first ever right heart catheterisation was performed by a German physician, Dr. Werner Forssman, on himself!

Right Heart Catheterization (RHC) is the gold standard for diagnosing and classifying pulmonary hypertension. The story behind its invention is captivating, highlighting the remarkable strides that individuals driven by a passion for science and innovation can take, often braving risks to their own well-being and even lives! Werner Forssmann was born in Berlin in 1904,

The fascinating story about how the first ever right heart catheterisation was performed by a German physician, Dr. Werner Forssman, on himself! Read Post »

“From Diagnosis of CTEPH to Triumph: Rishabh’s Journey of Resilience and Restoration”, May 31, 2023

Author: Pisana Ferrari, May 25, 2023, based on interview Introduction In the past few decades, significant strides have been made in the field of chronic thromboembolic pulmonary hypertension (CTEPH), encompassing enhanced disease comprehension, innovative therapies and surgical advancements. However, living with CTEPH continues to pose physical, practical, emotional, and social challenges for patients, families, and

“From Diagnosis of CTEPH to Triumph: Rishabh’s Journey of Resilience and Restoration”, May 31, 2023 Read Post »

“My Journey with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)”, Gabriele Valentini, May 29, 2023

Gabriele, a 47-year-old Italian national residing in Brescia, bravely opens up about his personal journey with Chronic Thromboembolic Pulmonary Hypertension (CTEPH), aiming to raise crucial awareness within the pulmonary hypertension community. By sharing his experience, he hopes to shed light on this condition and its impact, offering support and insights to those who may be

“My Journey with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)”, Gabriele Valentini, May 29, 2023 Read Post »

Pulmonary endarterectomy (PEA) Leads to Long-term QOL Improvement in People With CTEPH, study suggests, American Journal of Managed Care

Pulmonary endarterectomy (PEA) is the recommended first-line treatment for patients with chronic thromboembolic pulmonary hypertension (CTEPH), if they qualify for the procedure. Alternative therapies include balloon pulmonary angioplasty (BPA) or medical therapy. An article by Jared Kaltwasser for the American Journal of Managed Care, dated April 17, 2023, presents the results of a Swedish single

Pulmonary endarterectomy (PEA) Leads to Long-term QOL Improvement in People With CTEPH, study suggests, American Journal of Managed Care Read Post »

“Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study”, The Lancet, October 2022

RACE is a (completed) phase 3, multicentre, open-label, parallel-group, randomised controlled trial done in 23 French centres of expertise for pulmonary hypertension enrolling treatment-naive patients aged 18–80 years with newly diagnosed, inoperable chronic thromboembolic pulmonary hypertension and pulmonary vascular resistance of more than 320 dyn·s/cm5. A summary of the article is available on The Lancet

“Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study”, The Lancet, October 2022 Read Post »

TRANSLATE »
Scroll to Top